Home » Stocks » STTK

Shattuck Labs, Inc. (STTK)

Stock Price: $29.52 USD -2.48 (-7.75%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 1.30B
Revenue (ttm) 9.93M
Net Income (ttm) -36.60M
Shares Out 41.87M
EPS (ttm) -2.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $29.52
Previous Close $32.00
Change ($) -2.48
Change (%) -7.75%
Day's Open 31.97
Day's Range 29.20 - 32.48
Day's Volume 119,786
52-Week Range 17.51 - 60.52

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

AUSTIN, TX and DURHAM, NC, April 30, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pro...

1 week ago - GlobeNewsWire

AUSTIN, Texas and DURHAM, N.C., April 28, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusio...

1 week ago - GlobeNewsWire

AUSTIN, TX and DURHAM, NC, April 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pro...

1 month ago - GlobeNewsWire

AUSTIN, TX and DURHAM, NC, March 16, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pro...

1 month ago - GlobeNewsWire

– Initial dose-escalation data from Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), expected in the second half of 2021 –

1 month ago - GlobeNewsWire

AUSTIN, TX and DURHAM, NC, March 11, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pro...

1 month ago - GlobeNewsWire

AUSTIN, TX and DURHAM, NC, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion prot...

2 months ago - GlobeNewsWire

AUSTIN, TX & DURHAM, NC, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion protei...

2 months ago - GlobeNewsWire

AUSTIN, TX and DURHAM, NC, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion prot...

4 months ago - GlobeNewsWire

AUSTIN, TX and DURHAM, NC, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion prot...

4 months ago - GlobeNewsWire

AUSTIN, TX and DURHAM, NC, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion prot...

4 months ago - GlobeNewsWire

AUSTIN, TX and DURHAM, NC, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion prot...

5 months ago - GlobeNewsWire

– Initiated Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), for the treatment of ovarian cancer –

5 months ago - GlobeNewsWire

AUSTIN, TX and DURHAM, NC, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion prot...

5 months ago - GlobeNewsWire

AUSTIN, TX and DURHAM, NC, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion prot...

6 months ago - GlobeNewsWire

After a fast and furious week of activity, the IPO market is slated for a brief intermission in the coming week due to the approaching presidential election. Currently, there are no regular way US IPOs ...

Other stocks mentioned: AYLA, FUBO, GAN, INTZ, KC, KRON, SPRB
6 months ago - Seeking Alpha

DURHAM, N.C. and AUSTIN, Texas, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusi...

6 months ago - GlobeNewsWire

DURHAM, N.C. & AUSTIN, Texas--(BUSINESS WIRE)--Shattuck Labs, Inc. (“Shattuck”), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biol...

6 months ago - Business Wire

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...

Other stocks mentioned: CCL, BAM, FUBO, HEI, KRON
6 months ago - Benzinga

DURHAM, N.C. & AUSTIN, Texas--(BUSINESS WIRE)--Shattuck Labs, Inc. (“Shattuck”), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biol...

6 months ago - Business Wire

U.S. IPO Weekly Recap: Healthcare Dominates A 7 IPO Week

Other stocks mentioned: FUBO, INTZ, KRON, MAACU, MUDSU, NGACU, SPRB
6 months ago - Seeking Alpha

Shares of Shattuck Labs Inc. soared in their public debut, as they opened 30% above the initial public offering price. The stock's first trade was at $22.10 at 11:10 a.m.

6 months ago - Market Watch

Shattuck Labs Inc. said its initial public offering, which was upsized by about 19%, priced above the expected range at $17 a share, as the Texas-based biotechnology company focused on cancer treatments...

6 months ago - Market Watch

DURHAM, N.C. & AUSTIN, Texas--(BUSINESS WIRE)--Shattuck Labs, Inc. (“Shattuck”), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biol...

6 months ago - Business Wire

About STTK

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in A... [Read more...]

Industry
Pharmaceutical Preparation Manufacturing
IPO Date
Oct 9, 2020
Stock Exchange
NASDAQ
Ticker Symbol
STTK
Full Company Profile

Financial Performance

In 2020, Shattuck Labs's revenue was $9.93 million, an increase of 0.48% compared to the previous year's $9.89 million. Losses were -$36.60 million, 52.6% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Shattuck Labs stock is "Strong Buy." The 12-month stock price forecast is 57.00, which is an increase of 93.09% from the latest price.

Price Target
$57.00
(93.09% upside)
Analyst Consensus: Strong Buy